-- 週一,亞洲股市普遍上漲,交易員們正在權衡伊朗和華盛頓就波斯灣問題進行的談判結果,以及北京上週五晚間發布的證券業新規。 香港、上海和東京股市收漲,其他大多數地區性交易所也是如此。 在日本,日經225指數高開,最終收漲0.6%,交易員們正在評估本週在巴基斯坦舉行的美伊談判前景。 日經225指數上漲348.99點,收在58,824.89點,上漲個股數量超過下跌個股,比例為123比98。 瑞薩電子領漲,上漲6.4%,而住友製藥下跌5.9%。 在香港,恆生指數開盤走低,隨後收漲,最終收漲0.8%,投資人對中國證券業新規的接受度較高。 恆生指數上漲200.74點,收在26,361.07點,上漲個股數量超過下跌個股,比例為61比28。恆生科技指數當天上漲0.5%,內地產指數上漲0.3%。 信義光能領漲,漲幅達6.2%,中國石油下跌3.3%。 內地方面,上證綜指上漲0.8%,收在4,082.13點。 在產業新聞方面,中國證監會等監管機構於上週五晚間宣布修改相關法規,以加強市場監管並吸引長期投資。 整體而言,新規放寬了「策略投資者」(即機構資金)對中國上市公司的投資,尤其是對擁有強大投票權的A股的投資,同時也收緊了對非法出售股票和「擇業審計」行為的監管。 其他區域交易所方面,韓國綜合股價指數(KOSPI)上漲0.4%;台灣加權平均股價指數(TWSE)上漲0.4%;澳洲ASX 200指數上漲0.1%;新加坡海峽時報指數上漲0.1%;泰國指數持平。孟買Sensex指數在尾盤交易中下跌0.1%。 MSCI亞太地區所有國家指數當日上漲0.3%。
Related Articles
Arcus Biosciences Discontinues Phase 3 Lung Cancer Trial for Futility
Arcus Biosciences (RCUS) said Monday it discontinued its phase 3 STAR-121 study in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee recommended stopping the trial for futility.The study, conducted in collaboration with Gilead Sciences (GILD), evaluated domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment, the company said.The decision followed a pre-planned futility analysis indicating the treatment was unlikely to meet its primary endpoint.Shares of Arcus Biosciences were down 5% in Monday trading.Price: $23.05, Change: $-1.20, Percent Change: -4.95%
Sila Realty Trust to be Taken Private by Blue Owl Affiliates in $2.4 Billion Deal
Sila Realty Trust (SILA) agreed to be acquired and taken private by certain affiliates of Blue Owl Capital's (OWL) real estate unit in an all-cash deal worth roughly $2.4 billion.Shareholders of net lease real estate investment trust Sila will receive $30.38 per share, representing a 19% premium to the stock's closing price on Friday, the companies said Monday.The transaction, which requires approval from Sila's shareholders, is anticipated to complete in the second or third quarter of this year. Upon completion, the company will be delisted from the New York Stock Exchange."The consummation of this transaction will provide significant and immediate realized benefit to our shareholders," Sila Chief Executive Michael Seton said in a statement.Shares of Sila were up 19% in Monday trade. Asset manager Blue Owl rose 1%.Sila, which is focused on investing in healthcare facilities, said its portfolio comprised 137 real estate properties and three undeveloped land parcels in the US as of end-March. Data on its website showed its portfolio includes 86 medical outpatient buildings, 25 inpatient rehabilitation facilities, and 26 surgical and specialty facilities."This transaction provides us with a compelling opportunity to acquire a scaled portfolio with durable cash flows and attractive long-term growth characteristics, while further expanding Blue Owl managed funds' exposure to an asset class and sector we view as both resilient and essential given its critical role in both society and the economy," Marc Zahr, co-president and global head of real assets at Blue Owl, said.In February, Sila reported fourth-quarter adjusted funds from operations of $0.55 per share, up from $0.54 a year ago. Revenue rose to $50.7 million from $46.5 million.Sila plans to pay up to two regular quarterly dividends ahead of deal completion.Price: $30.44, Change: $+4.90, Percent Change: +19.19%
Carnival Shareholders Approve Single Company Structure, Redomiciliation
Carnival (CCL, CUK) said Monday that majority of its shareholders approved the proposal to simplify its dual-listed structure into a single company and the redomiciliation of Carnival Corporation to Bermuda from Panama.The company said it expects the proposed changes to become effective on May 7.Price: $28.69, Change: $-0.53, Percent Change: -1.81%